A Study On The Safety And Effectiveness Of 23-valent Pneumonia Vaccine In HIV-infected People

ObjectiveTo study the safety and efficacy of 23-valent pneumonia vaccine(PPV23)in HIV-infected patients for the HIV-infected population in China.Vaccination and the reduction of opportunistic infections provide scientific evidence.MethodsBased on adult HIV-infected persons who voluntarily received PPV23 vaccine in Lanshan County,Hunan Province,from January 2018 to May 2019 PPV23 pneumonia vaccine was administered to the study population using a uniform questionnaire administered either by telephone or face-to-face by a trained investigator.A survey was conducted on the study subjects.The survey included demographic characteristics,AIDS/HIV-related test parameters and clinical characteristics of the subjects,pre-and post-vaccination.Pulmonary infections,as well as clinical treatment expenditures and side effects of vaccination,while collecting peripheral venous serum from the study population Conduct laboratory tests.ResultsA total of 145 subjects were included in this study.Males accounted for 70.34%(102/145)and females for 29.66%(43/145);age distribution.The proportion of women under 40 years of age was 20.69 per cent(30/145),and 43.45 per cent(63/145)were between 40 and 59 years of age.145),and 35.86 %(52/145)were 60 years and older.The incidence of respiratory tract infections and pneumonia among HIV-infected persons was significantly reduced after PPV23 pneumonia vaccination(p<0.05).Significantly fewer illnesses(p<0.05),average length of hospital stay and total cost of hospital treatment than vaccination.before vaccination(p<0.05).After PPV23 pneumonia vaccination in HIV-infected individuals,67 of 145 surveyed respondents Antibodies associated with PPV23 pneumonia vaccine have been tested before and after vaccination,and the prevaccination seropositivity rate was 16.41%,56(83.58%)were negative for serum-associated antibodies,and the positive conversion rate after vaccination was 91.07% and antibody positivity rate was 92.54%.Only 1 person(0.69 %)had injection site pain2 weeks after PPV23 vaccination,which was relieved by prompt treatment,no Other discomfort.The cost-benefit analysis was based on the cost of medical visits by survey respondents in the year before and after vaccination,with 13 visits for pneumonia before vaccination and medical insurance coverage.The post-vaccination cost per capita is$3,207;one person with pneumonia within a year of vaccination costs$100 for an outpatient visit.The cost of vaccination is $212.The net benefit is $2,958 per capita,which has a good economic impact.ConclusionPPV23 pneumonia vaccination of HIV-infected patients has better efficacy,safety,effectiveness,and economic benefits.